Relmada Therapeutics Inc. (RLMD) 2.0100 $RLMD Addiction

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Relmada Therapeutics Inc. (RLMD) 2.0100 $RLMD

Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 8.77 (+0.05), PFE: 33.99 (+0.05), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), ACUR: 0.80 (+0.03), JNJ: 102.30 (+0.47), INSY: 59.00 (+0.17), TRGT: 2.32 (unch), GILD: 109.30 (+0.56), AZN: 69.29 (-0.81), ABBV: 65.99 (+0.02), ARNA: 4.25 (unch)

Relmada Therapeutics announces USPTO's patent allowance for proprietary SECUREL abuse deterrent technology platform
M2 - Wed May 13, 4:34AM CDT
Pharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) disclosed on Tuesday that its new patent relating to its proprietary SECUREL abuse deterrent technology platform was allowed for issuance by the US Patent and Trademark Office (USPTO).

Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering SECUREL(TM), its Abuse-Deterrent, Extended-Release, Technology Platform for Opioids
PR Newswire - Tue May 12, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that Application No. 12/597,702 relating to its proprietary SECUREL abuse deterrent technology platform was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO).

Global Insulin Patch Market Opportunity Analysis 2015
M2 - Wed May 06, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rkj3v9/global_insulin) has announced the addition of the "Global Insulin Patch Market Opportunity Analysis" report to their offering. Highly advanced technology like ultrasound and iontophoresis are being used for the development of modern insulin patches. Depending upon the type of technique, their prices may vary which may be out of reach of several patients. In long-term, it would be considered as inexpensive but high upfront cost may deter some diabetic patients. Benefits like greater control over blood glucose levels and ease of utilization are one of the most significant benefits of these technologies. It is expected that investigators would also explore the techniques like electroporation, thermal ablation and microdermabrasion for making insulin patches. These techniques are expected to increase the cost effectiveness due to which their market penetration would increase. In coming years, it is expected that investigators would be able to come forth with insulin patches having higher pharmacological benefits with lesser prices. Besides this, newer modalities are also expected to be developed due to which more sales are expected to be generated. Development of insulin patches are expected to pave the path for the development of large molecule based transdermal patches. This is going to be a major technological success due to which large number of patients would get more therapeutic benefits. Due to increased indications, more revenues are expected to generate from this field. Both molecules and formulations have to be revisited that will lead to new innovations. Moreover, pharmaceutical companies engaged in the production of insulin patches may venture in other diseases segment by using same technology. Insulin patches have yet not made place in global market but they will definitely encourage the other pharmaceutical companies to follow the lead. Pharmaceutical companies are expected to launch the first insulin patch in global market in next few years. "Global Insulin Patch Market Opportunity Analysis" Report Highlights: - Introduction to Insulin Patch - Mechanism Iontophoresis, Ultrasonic & Microneedle Insulin Patch - Global Insulin Patch Market Analysis - Global Insulin Patch Clinical Pipeline by Company, Indication & Phase - Global Insulin Patch Clinical Pipeline: 9 Patches - Highest Phase of Insulin Patch Development: Phase-II - Insulin Patch Patent Analysis Key Topics Covered: 1. Introduction to Insulin Patch 2. Comparison between Insulin Patches & Other Insulin Modalities 3. Mechanism of Insulin Patches 4. Emerging Trends in Insulin Delivery 5. Global Insulin Patch Market Analysis 6. Global Insulin Patch Market Dynamics 7. Future Prospects of Insulin Patch Market 8. Global Insulin Patch Clinical Pipeline by Company, Indication & Phase 9. Discontinued Insulin Patch in Clinical Pipeline 10. Competitive Landscape - Dermisonics - Encapsulation Systems - Encapsulife - Mesoblast - NeurogesX - NOLabs AB - Novo Nordisk - Phosphagenics - Relmada Therapeutics - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/rk...al_insulin
NVO: 56.75 (+0.06), ZSAN: 10.41 (+0.63)

Relmada Therapeutics Commences Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine
PR Newswire - Tue Apr 21, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the commencement of a proof-of-concept pharmacokinetic study with its novel formulations of oral, enteric-coated buprenorphine (collectively BuTab, or REL-1028) being developed for both chronic pain and opioid dependence indications.

Relmada Therapeutics Receives Health Canada Clearance to Further Explore Promising NMDA Receptor Antagonist d-Methadone (REL-1017)
PR Newswire - Thu Apr 16, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has received clearance from Health Canada to continue dose escalation and explore higher doses of d-Methadone (REL-1017), the company's N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain. In the Phase 1 pharmacokinetic and pharmacodynamic study in healthy volunteers not previously exposed to opioid therapy, d-Methadone demonstrated a good safety profile with no dose-limiting side effects after the original four cohorts were exposed to increasingly higher doses. The trial will continue dose-escalation with the additional cohorts.

Relmada Therapeutics elects Dr Lisa Nolan as SVP of business development
M2 - Thu Apr 09, 5:43AM CDT
Pharmaceutical company
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 46

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 52

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 42

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 50

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 16

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 0

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 23

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 65

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 229

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 48

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading

Top 5 Most Recently Viewed Articles

Liberty Media Corp Achieves Milestone with Stock Surge

Updated Category News Views 203

Liberty Media Corporation Reaches New 52-Week High Liberty Media Corp (FWONA), a significant player in the media and entertainment sectors, has recently achieved a landmark 52-week high in its stock price, soaring to $75.71. This impressive rise has brought attention to the company's strong market performance, reflecting a substantial gain of 31.03% over the past year....

Continue Reading
Telegram's Pavel Durov Responds to Content Moderation Criticism

Updated Category News Views 200

Pavel Durov Addresses Concerns Over Telegram's Moderation Pavel Durov, the CEO of Telegram, has recently addressed the growing concerns about the platform’s moderation practices. In a message to his large audience of over 12 million subscribers, Durov pledged that the company would take steps to respond to the criticism regarding how Telegram handles content management....

Continue Reading
FiscalNote Expands Its Reach with New Public Sector Customers

Updated Category News Views 107

FiscalNote Expands Its Reach with New Public Sector Customers FiscalNote Holdings, Inc. (NYSE: NOTE), renowned for its AI-driven enterprise SaaS technologies, has recently made headlines by securing a myriad of new agreements across the U.S. public sector. These contracts span the federal government's three branches, showcasing the Company's celebrated suite of products...

Continue Reading
Bluejay Diagnostics to Showcase Symphony IL-6 Findings at SAEM

Updated Category News Views 117

Exciting Announcement from Bluejay Diagnostics Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has recently made a remarkable announcement that will resonate within the medical community. This innovative healthcare company has had an abstract accepted for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting. This significant event is scheduled to take...

Continue Reading
Clean Maine Carbon Launches Biochar Carbon Credits Through Puro.earth

Updated Category News Views 334

Clean Maine Carbon's Groundbreaking Initiative Clean Maine Carbon (CMC) has taken a significant step forward in sustainable carbon removal by launching its first biochar CO2 Removal Certificates (CORCs). Teaming up with Flowcarbon as its carbon development partner, CMC's move marks a pivotal moment in the quest for innovative solutions to combat climate change. The Role...

Continue Reading